Autonomix Medical (NASDAQ:AMIX) Raised to Sell at Wall Street Zen

Autonomix Medical (NASDAQ:AMIX) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $42.00.

Autonomix Medical Price Performance

NASDAQ:AMIX opened at $3.78 on Friday. The firm has a 50-day moving average of $5.59 and a two-hundred day moving average of $6.82. The stock has a market cap of $3.67 million, a P/E ratio of -0.09 and a beta of -0.96. Autonomix Medical has a 1-year low of $2.44 and a 1-year high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. As a group, equities analysts expect that Autonomix Medical will post -20.17 earnings per share for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a medical device company developing catheter-based technologies intended to diagnose and treat conditions involving the peripheral nervous system. The company’s platform uses a miniature sensing chip integrated into a catheter to detect and measure nerve signals in targeted areas of the body.

Autonomix is initially focused on applications in pain management, including the detection and treatment of nerves associated with chronic and cancer-related pain. Its technology is designed to help physicians identify relevant nerves more precisely and guide procedures such as targeted nerve ablation or other therapeutic interventions.

The company’s development programs remain subject to clinical testing, regulatory review and authorization before any products can be broadly commercialized.